The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard ...
The targeted RAS inhibitor daraxonrasib was found to be safe and showed signs of efficacy in patients with previously treated ...
Daraxonrasib showed durable responses and improved survival in patients with RAS-mutant pancreatic cancer compared with ...
Data contributed to the scientific and clinical rationale for RASolute 302, a pivotal Phase 3 trial in second line treatment ...
MedPage Today on MSN
Safety Data on the Novel Pancreatic Cancer Drug Available by Early Access
Rash, diarrhea, nausea, and other potential side effects to expect ...
The targeted RAS inhibitor therapy daraxonrasib demonstrated the potential to improve patient outcomes over current standard ...
An experimental drug from Revolution Medicines that nearly doubled survival time for patients with advanced pancreas cancer ...
Daraxonrasib shows promising results in treating pancreatic cancer, potentially revolutionizing care with its effectiveness ...
Suneel Kamath, MD, knows too well the sense of helplessness that comes with living through what he calls “the doughnut hole.” ...
Good day, and thank you for standing by. Welcome to the Revolution Medicines Q1 2026 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results